Early trial for young cancer patients halted before starting
NCT ID NCT04500548
Summary
This early-phase study aimed to test the safety and effectiveness of a two-drug immunotherapy combination (nivolumab and ipilimumab) in children, teens, and young adults. It was specifically for patients whose cancers had returned or stopped responding to standard treatments and had a high number of genetic mutations. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030, United States
-
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4, Canada
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.